MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

PF-04217903 mesylate

CAS No. : 956906-93-7

MCE 站：PF-04217903 mesylate

产品活性：PF-04217903 mesylate 是一种高效的ATP竞争性 c-Met 激酶抑制剂，K_i 为 4.8 nM。PF-04217903 mesylate 相对于 208 个激酶显示出 1000 倍以上的选择性。具有抗血管生成特性。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：c-Met/HGFR

In Vitro: PF-04217903 mesylate (0.1-10000 nM; 48-72 hours) inhibits proliferation of c-Metamplified human GTL-16 gastric carcinoma ａnd H1993 NSCLC cells with IC₅₀ values of 12 ａnd 30 nM, respectively.
PF-04217903 mesylate induces apoptosis of GTL-16 cells (IC₅₀=31 nM) .
PF-04217903 mesylate also inhibits HGF-mediated cell migration ａnd Matrigel invasion in several c-Metoverexpressing tumor cell lines such as human NCI-H441 lung carcinoma ａnd HT29 colon carcinoma with IC50 values comparable with those for inhibition of c-Met phosphorylation in these cell lines (IC₅₀= 7-12.5 nM).
PF-04217903 mesylate displays similar potency to inhibit the activity of c-Met-H1094R, c-Met-R988C, ａnd c-Met-T1010I with IC₅₀ of 3.1 nM, 6.4 nM, ａnd 6.7 nM, respectively, but has no inhibitory activity against c-Met-Y1230C with IC₅₀ of >10 μM.

In Vivo: PF-04217903 mesylate (1-30 mg/kg; p.o.; daily for 16 days) shows dose-dependent tumor growth inhibition, which correlated with the inhibition in c-Met phosphorylation in these tumors .
PF-04217903 mesylate (5-50 mg/kg, p.o.; once daily for 3 days) dose dependently inhibits c-Met, Gab-1, Erk1/2, ａnd AKT phosphorylation ａnd induced apoptosis (cleaved caspase-3) in U87MG xenograft tumors at all dose levels. PF-04217903 mesylate shows a significant dose-dependent reduction of human IL-8 levels in both the U87MG ａnd GTL-16 models ａnd decreases human VEGFA levels in the GTL-16 model. PF-04217903 mesylate strongly induces phospho-PDGFRβ levels in U87MG xenograft tumors.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Lung Cancer Compound Library  |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Cancer Stem Cells Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Cytokine Inhibitors Library  |  AMG-208  |  DS-1205b free base  |  c-Met-IN-1  |  Glumetinib  |  Savolitinib  |  c-Met-IN-11  |  ABN401  |  Foretinib  |  Bafisontamab  |  MK-2461  |  Dalmelitinib  |  MK-8033 hydrochloride  |  c-Met-IN-12  |  MET kinase-IN-4  |  Telisotuzumab vedotin  |  Cabozantinib  |  Multi-kinase-IN-5  |  AC-386  |  c-Met inhibitor 1  |  Pamufetinib  |  Mefatinib-d₆  |  Tyrosine kinase-IN-4  |  PHA-665752  |  JNJ-38877618  |  SU11274  |  AMG-458  |  SCR-1481B1  |  c-Met-IN-2

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。